Cargando…

Perspective on the current state of the LRRK2 field

Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to grow, aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Taymans, Jean-Marc, Fell, Matt, Greenamyre, Tim, Hirst, Warren D., Mamais, Adamantios, Padmanabhan, Shalini, Peter, Inga, Rideout, Hardy, Thaler, Avner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314919/
https://www.ncbi.nlm.nih.gov/pubmed/37393318
http://dx.doi.org/10.1038/s41531-023-00544-7
_version_ 1785067410437439488
author Taymans, Jean-Marc
Fell, Matt
Greenamyre, Tim
Hirst, Warren D.
Mamais, Adamantios
Padmanabhan, Shalini
Peter, Inga
Rideout, Hardy
Thaler, Avner
author_facet Taymans, Jean-Marc
Fell, Matt
Greenamyre, Tim
Hirst, Warren D.
Mamais, Adamantios
Padmanabhan, Shalini
Peter, Inga
Rideout, Hardy
Thaler, Avner
author_sort Taymans, Jean-Marc
collection PubMed
description Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to grow, affirming decisions made years ago to therapeutically target this enzyme for PD. Markers of LRRK2 activity, with potential to monitor disease progression or treatment efficacy, are also under development. Interestingly, there is a growing understanding of the role of LRRK2 outside of the central nervous system in peripheral tissues such as gut and immune cells that may also contribute to LRRK2 mediated pathology. In this perspective, our goal is to take stock of LRRK2 research by discussing the current state of knowledge and critical open questions in the field.
format Online
Article
Text
id pubmed-10314919
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103149192023-07-03 Perspective on the current state of the LRRK2 field Taymans, Jean-Marc Fell, Matt Greenamyre, Tim Hirst, Warren D. Mamais, Adamantios Padmanabhan, Shalini Peter, Inga Rideout, Hardy Thaler, Avner NPJ Parkinsons Dis Perspective Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to grow, affirming decisions made years ago to therapeutically target this enzyme for PD. Markers of LRRK2 activity, with potential to monitor disease progression or treatment efficacy, are also under development. Interestingly, there is a growing understanding of the role of LRRK2 outside of the central nervous system in peripheral tissues such as gut and immune cells that may also contribute to LRRK2 mediated pathology. In this perspective, our goal is to take stock of LRRK2 research by discussing the current state of knowledge and critical open questions in the field. Nature Publishing Group UK 2023-07-01 /pmc/articles/PMC10314919/ /pubmed/37393318 http://dx.doi.org/10.1038/s41531-023-00544-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Perspective
Taymans, Jean-Marc
Fell, Matt
Greenamyre, Tim
Hirst, Warren D.
Mamais, Adamantios
Padmanabhan, Shalini
Peter, Inga
Rideout, Hardy
Thaler, Avner
Perspective on the current state of the LRRK2 field
title Perspective on the current state of the LRRK2 field
title_full Perspective on the current state of the LRRK2 field
title_fullStr Perspective on the current state of the LRRK2 field
title_full_unstemmed Perspective on the current state of the LRRK2 field
title_short Perspective on the current state of the LRRK2 field
title_sort perspective on the current state of the lrrk2 field
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314919/
https://www.ncbi.nlm.nih.gov/pubmed/37393318
http://dx.doi.org/10.1038/s41531-023-00544-7
work_keys_str_mv AT taymansjeanmarc perspectiveonthecurrentstateofthelrrk2field
AT fellmatt perspectiveonthecurrentstateofthelrrk2field
AT greenamyretim perspectiveonthecurrentstateofthelrrk2field
AT hirstwarrend perspectiveonthecurrentstateofthelrrk2field
AT mamaisadamantios perspectiveonthecurrentstateofthelrrk2field
AT padmanabhanshalini perspectiveonthecurrentstateofthelrrk2field
AT peteringa perspectiveonthecurrentstateofthelrrk2field
AT rideouthardy perspectiveonthecurrentstateofthelrrk2field
AT thaleravner perspectiveonthecurrentstateofthelrrk2field